APPROVED_FOR_MARKETINGNot Applicable

Early Access Program of Lazertinib in Republic of Korea

Plain-language summary

This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged at least 19 years * Patients who have written consent for use of personal and medical information for the study purpose * Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously. Exclusion Criteria: * Patients with hypersensitivity to Lazertinib or its any ingredients * Patients who belong to contraindication listed on lazertinib label in Korea * Patients who are treated for an indication not approved for the use of Lazertinib * Women who are pregnant or may possibly become pregnant

Trial details

NCT IDNCT04829422

SponsorYuhan Corporation

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Lung Cancer trials